

Contents

	Page No.
List of Tables	i-ii
List of Figures	iii-vi
List of Abbreviations and Symbols	vii-viii
Preface	ix-x
1. Introduction	01-05
2. Literature review	06-42
2.1 Cancer	06
2.1.1 Brest	07
2.1.2 Breast cancer	08
2.1.3 Etiology and causes	08
2.1.4 Therapeutic approaches	10
2.2 Drug and Excipients	16
2.2.1 Docetaxel	16
2.2.2 Polymers	21
2.3 Polymeric Nanoparticles	25
2.3.1 Methods for preparation	26
2.3.2 Drug release	27
2.3.3 Drug delivery	32
2.3.4 Nano-size drug delivery	33
2.3.5 Targeting drug delivery	35
2.3.6 Stimuli-responsive drug delivery	38
2.3.7 pH-responsive drug delivery	39
3. Plan of study	43-47
4. Materials and methods	48-90
4.1 Materials	50
4.1.1 Chemicals	50
4.1.2 Equipments	51
4.1.3 Animals and cell lines	53
4.1.4 Software	53
4.2 Preformulation studies	54
4.2.1 Physical observation	54
4.2.2 FTIR interpretation	55
4.2.3 UV-Visible spectroscopy	56
4.2.4 HPLC method development and validation	57

4.3	Preparation of PHBV PVA polymeric nanoparticles	63
	4.3.1 Formulation of docetaxel loaded nanoparticles	63
	4.3.2 Risk assessment studies	64
	4.3.3 Factor screening design studies	66
	4.3.4 Optimization and statistical analysis	66
	4.3.5 Determination of particle shape and size	67
	4.3.6 Determination of surface charge and density	67
	4.3.7 Determination of entrapment efficiency	68
	4.3.8 In vitro drug release studies	69
4.4	Preparation of PHBV PF127 polymeric nanoparticles	69
	4.4.1 Formulation of docetaxel loaded nanoparticles	69
	4.4.2 Risk assessment studies	70
	4.4.3 Optimization and statistical analysis	71
	4.4.4 Morphological studies	73
	4.4.5 Particle size and surface charge	73
	4.4.6 Determination of entrapment efficiency	74
	4.4.7 In vitro drug release studies	74
4.5	Preparation of PHBV TPGS polymeric nanoparticles	75
	4.5.1 Formulation of docetaxel loaded nanoparticles	75
	4.5.2 Formulation by design approach	76
	4.5.3 Morphological studies	77
	4.5.4 Particle size and surface charge	78
	4.5.5 Determination of entrapment efficiency	78
	4.5.6 In vitro drug release studies	79
4.6	Preparation of PHBV PLH PE-PEG polymeric nanoparticles	79
	4.6.1 Formulation of docetaxel loaded nanoparticles	79
	4.6.2 Formulation by design approach	81
	4.6.3 Morphological studies	81
	4.6.4 Particle size and surface charge	82
	4.6.5 Proton (¹ H) NMR spectroscopy	82
	4.6.6 Determination of entrapment efficiency	83
	4.6.7 In vitro drug release studies	83
4.7	Cytotoxicity studies	84
4.8	Cell uptake studies	85
4.9	Pharmacokinetic study	85
4.10	In vivo-in silico and IVIVC studies	86
4.11	In vivo anticancer activity	87
4.12	Drug-plasma interaction and hemolysis studies	88
4.13	Stability study	89

4.14	Statistical analysis	89
5.	Results and discussion	91-165
5.1	Preformulation studies	91
	5.1.1 UV spectrophotometric analysis	91
	5.1.2 HPLC analytical method development and validation	92
	5.1.3 Conclusion	101
5.2	Preparation of PHBV PVA DTX polymeric nanoparticles	102
	5.2.1 Plackett Burman design	102
	5.2.2 Box Behnken design	103
	5.2.3 Morphological study	108
	5.2.4 Average particle size and zeta potential	109
	5.2.5 In vitro release of docetaxel	111
5.3	Preparation of PHBV PF127 DTX polymeric nanoparticles	112
	5.3.1 Plackett Burman screening studies	112
	5.3.2 Optimization and statistical analysis	112
	5.3.3 Morphological study	118
	5.3.4 Average particle size and zeta potential	118
	5.3.5 In vitro release	120
5.4	Preparation of PHBV TPGS DTX polymeric nanoparticles	121
	5.4.1 Optimization studies	121
	5.4.2 Plackett Burman factor screening design	122
	5.4.3 Box Behnken design and statistical analysis	124
	5.4.4 Morphological study	128
	5.4.5 Average particle size and zeta potential	128
	5.4.6 In vitro release	130
5.5	Preparation of PHBV PLH PEG DTX polymeric NPs	131
	5.5.1 Optimization and statistical analysis	131
	5.5.2 Average particle size, zeta potential and PDI	137
	5.5.3 Entrapment efficiency	139
	5.5.4 Surface morphology	139
	5.5.5 ¹ H NMR spectroscopy	141
	5.5.6 In vitro drug release studies	142
5.6	Drug excipient and drug plasma interaction study	143
	5.6.1 FTIR spectroscopy	143
	5.6.2 Powder XRD study	145
	5.6.3 DSC study	146
	5.6.4 Interaction with rat plasma	148
5.7	Cytotoxicity studies	149
5.8	Cellular uptake and cell viability studies	151

5.9	Evaluation of hemolysis and platelet aggregation	153
5.10	Pharmacokinetic studies	155
5.11	In silico prediction and in vitro in vivo correlation	157
5.12	In vivo anticancer activity	159
5.13	Stability studies	164
6.	Conclusion	166-167
7.	References	168-187
8.	Publications	-----

